141 related articles for article (PubMed ID: 12413738)
1. A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.
Huang J; Dong X; Liu Z; Qin L; Chen YH
Immunol Lett; 2002 Dec; 84(3):205-9. PubMed ID: 12413738
[TBL] [Abstract][Full Text] [Related]
2. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
Dong XN; Xiao Y; Chen YH
Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
[TBL] [Abstract][Full Text] [Related]
3. The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41.
Wang Z; Liu Z; Cheng X; Chen YH
Microbiol Immunol; 2005; 49(8):703-9. PubMed ID: 16113499
[TBL] [Abstract][Full Text] [Related]
4. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
Xiao Y; Dong X; Chen Y
Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
[TBL] [Abstract][Full Text] [Related]
5. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine.
Xiao Y; Dong XN; Chen YH
Hybridoma; 2000 Aug; 19(4):347-50. PubMed ID: 11001409
[TBL] [Abstract][Full Text] [Related]
6. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.
Zhang G; Chen YH
Immunobiology; 2003; 207(4):259-64. PubMed ID: 12952348
[TBL] [Abstract][Full Text] [Related]
7. HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies.
Tian H; Xiao Y; Zhu M; Chen YH
Int Immunopharmacol; 2001 Apr; 1(4):763-8. PubMed ID: 11357888
[TBL] [Abstract][Full Text] [Related]
8. Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.
Li H; Liu ZQ; Ding J; Chen YH
Immunol Lett; 2002 Nov; 84(2):153-7. PubMed ID: 12270553
[TBL] [Abstract][Full Text] [Related]
9. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
Ding J; Lu Y; Chen Y
FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
Lu Y; Ding J; Chen YH
Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
[TBL] [Abstract][Full Text] [Related]
11. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody.
Xiao Y; Zhao Y; Lu Y; Chen YH
Immunol Invest; 2000 Feb; 29(1):41-50. PubMed ID: 10709845
[TBL] [Abstract][Full Text] [Related]
12. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
13. The neutralizing epitope ELDKWA on HIV-1 gp41: genetic variability and antigenicity.
Dong XN; Wu Y; Chen YH
Immunol Lett; 2005 Oct; 101(1):81-6. PubMed ID: 15951025
[TBL] [Abstract][Full Text] [Related]
14. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
15. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
16. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
Arnold GF; Velasco PK; Holmes AK; Wrin T; Geisler SC; Phung P; Tian Y; Resnick DA; Ma X; Mariano TM; Petropoulos CJ; Taylor JW; Katinger H; Arnold E
J Virol; 2009 May; 83(10):5087-100. PubMed ID: 19279101
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies.
Zhang G; Lu H; Lu Y; Jiang S; Chen YH
Immunobiology; 2005; 210(9):639-45. PubMed ID: 16323702
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
Neurath AR; Strick N; Lin K; Jiang S
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
[TBL] [Abstract][Full Text] [Related]
20. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
